These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 6902727)

  • 1. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.
    Halbwachs L; Leveillé M; Lesavre P; Wattel S; Leibowitch J
    J Clin Invest; 1980 Jun; 65(6):1249-56. PubMed ID: 6902727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway.
    Hiramatsu M; Tsokos GC
    Clin Immunol Immunopathol; 1988 Jan; 46(1):91-9. PubMed ID: 2826058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
    Sobel AT; Cooper NR; Schreiber RD
    J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; van Es LA
    Clin Exp Immunol; 1984 Jun; 56(3):614-20. PubMed ID: 6430610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event.
    Spitzer RE; Stitzel AE; Tsokos GC
    J Pediatr; 1990 May; 116(5):S103-8. PubMed ID: 2329411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibitory effect of factor J on the alternative complement pathway.
    González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
    J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.
    Tanuma Y; Ohi H; Hatano M
    Immunology; 1989 Dec; 68(4):445-8. PubMed ID: 2532618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
    Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J
    J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
    Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
    Front Immunol; 2019; 10():886. PubMed ID: 31068950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
    Daha MR; van Es LA
    J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.